Tenon Medical, Inc. announced on March 24, 2025, that the U.S. Food and Drug Administration (FDA) has granted clearance for an expanded indication for its Catamaran® SI Joint Fusion System. The system can now be used to augment thoracolumbar fusion.
This expanded indication allows the Catamaran system to treat the SI joint as either a stand-alone treatment or to support a spinal fusion. This significantly increases the versatility and utility of the device for surgeons.
The FDA clearance opens a sizable new market opportunity for Tenon Medical, enabling its technology to address a broader patient population and integrate into more complex spinal procedures. This is expected to drive increased adoption and market share.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.